Establishment Labs Holdings (ESTA) just published three-year clinical results on its Mia Femtech implant, highlighting strong safety outcomes and high satisfaction among both patients and surgeons. The study offers valuable insight into ongoing product safety and effectiveness.

With its positive clinical update, Establishment Labs Holdings has caught renewed attention. After a quiet start to the year, momentum is building; the stock’s 1-month share price return of nearly 25% and a 9.2% total shareholder return over 12 months hint at renewed optimism from investors, further supported by the company’s long-term track record.

If you’re interested in uncovering more names in the medical device and healthcare space, here’s a chance to explore other potential opportunities: See the full list for free.

With shares climbing and the latest product update impressing, is Establishment Labs trading at an attractive valuation that leaves room for further gains, or is future growth already factored into today’s price?

Most Popular Narrative: 11% Undervalued

At $49.32, the latest share price sits below the consensus fair value estimate of $55.44. Investors are closely watching whether this gap reflects untapped growth or market caution, and the narrative’s underlying assumptions may provide fresh angles on the opportunity ahead.

Accelerating surgeon adoption and utilization curve in the U.S., combined with further account additions and growing patient demand (amplified by patient-driven requests and social media engagement), positions the company for continued strong revenue growth and sustainable market share gains in a large, culturally receptive, and increasingly affluent market.

Want to know what powers this bullish narrative? The foundation is bold growth targets in both revenue and profit margins. These numbers could define the company’s valuation. Discover the ambitious projections behind the fair value.

Result: Fair Value of $55.44 (UNDERVALUED)

However, ongoing high expenses and slower-than-expected international expansion could challenge the pace of Establishment Labs Holdings' anticipated revenue and margin growth.

Another View: Our DCF Model Suggests Overvaluation

While traditional valuation points to Establishment Labs being undervalued, our SWS DCF model presents a more cautious perspective. According to this approach, the current price of $49.32 stands above its fair value estimate of $31.70, which suggests that the stock could be overvalued if cash flows materialize more conservatively. Will real-world growth align with these optimistic expectations?

Build Your Own Establishment Labs Holdings Narrative

If you want to develop your own view or take your research further, you can build a personalized narrative based on the latest data in under three minutes. Do it your way

A great starting point for your Establishment Labs Holdings research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.

Looking for More Winning Investment Ideas?

Smart investors never wait for the crowd. Get ahead by unlocking opportunities in exciting, fast-moving sectors with these tailored screens from Simply Wall Street.

• Unlock explosive potential and tap into early-stage market movers by checking out these 3596 penny stocks with strong financials, which are making waves with solid financials and growth stories.
• Target future-shaping breakthroughs and put your portfolio at the forefront with these 24 AI penny stocks, designed to highlight standout companies in artificial intelligence.
• Boost your income stream by finding these 17 dividend stocks with yields > 3%, which features opportunities delivering stable yields above 3% and setting a new standard for reliable returns in any market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.